Skip to content
Open in App
Adc Thera logo

Adc Thera

web2

ADC Therapeutics develops and commercializes antibody-drug conjugate medicines for patients wit...

Symbol ยท ADCT
Company profile

About

ADC Therapeutics develops and commercializes antibody-drug conjugate medicines for patients with blood cancers, including its marketed treatment for relapsed or refractory large B-cell lymphoma. Its principal commercial product is ZYNLONTA, a CD19-directed therapy used after at least two prior lines of systemic treatment for eligible adults. The company also studies combinations and potential label expansions in clinical trials, including research in earlier treatment settings and other lymphomas. ADC Therapeutics SA is incorporated in Switzerland and has subsidiaries in the United States and United Kingdom. Its common shares trade on the New York Stock Exchange under the symbol ADCT.

Explore by sector

Explore this sector

Market identity

Exchange listings

Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.

ExchangeNYSEPrimary symbol: ADCT
Expert coverage

Adc Thera profile.

Orbitrum research

Expert coverage

No published expert evaluations are available for this project yet.

Orbitrum Academy

Learn how to read a project assessment